Eli Lilly and Company $LLY Stock Holdings Decreased by Sarasin & Partners LLP

Sarasin & Partners LLP lessened its position in Eli Lilly and Company (NYSE:LLY) by 6.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 131,497 shares of the company’s stock after selling 8,858 shares during the quarter. Eli Lilly and Company makes up about 1.5% of Sarasin & Partners LLP’s holdings, making the stock its 29th biggest holding. Sarasin & Partners LLP’s holdings in Eli Lilly and Company were worth $141,317,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Miller Global Investments LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $33,000. Sumitomo Mitsui Financial Group Inc. acquired a new stake in shares of Eli Lilly and Company in the second quarter worth $27,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after buying an additional 16 shares during the period. Evolution Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company during the second quarter valued at $29,000. Finally, Steph & Co. raised its position in Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after buying an additional 29 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $910.59 on Tuesday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The business’s 50-day moving average price is $1,019.76 and its two-hundred day moving average price is $960.48. The company has a market capitalization of $860.34 billion, a P/E ratio of 39.68, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s quarterly revenue was up 42.6% on a year-over-year basis. During the same period last year, the business earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Cantor Fitzgerald increased their price objective on Eli Lilly and Company from $985.00 to $1,205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. CICC Research upped their target price on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.44.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Expanded patient access/pricing for Zepbound — Lilly will offer a self-pay option starting at $299/month for a low dose and expand distribution via LillyDirect and major pharmacies, which could widen the addressable market and reduce payer friction. Eli Lilly Expands Zepbound Access
• Positive Sentiment: Analysts trimming and raising targets after strong quarterly results — multiple outlets note analyst upgrades and upside estimates following Lilly’s February quarter beats and raised FY‑2026 EPS guidance, supporting investor confidence. Analyst Upside Coverage
• Positive Sentiment: Positive Phase‑3 ADorable‑1 topline results announced — a favorable readout (topline) from a Phase‑3 trial bolsters pipeline optionality beyond weight‑loss products, which could add long‑term value if confirmed in full data and regulatory filings. ADorable-1 Topline Results
• Positive Sentiment: Manufacturing / international expansion discussions — Lilly leadership is engaged with Indian officials on “Make in India” steps, signaling potential capacity/market expansion outside the U.S. that could support production and revenue growth. Make in India Meeting
• Neutral Sentiment: Executives ramping China engagement — Lilly joined U.S. peers at the China Development Forum; management signals cautious investment in China, which is an opportunity for growth but carries geopolitical and execution risks. China Development Forum Coverage
• Neutral Sentiment: Local permitting / community concerns around new plant — planners in Lehigh Valley will discuss traffic and other issues tied to a proposed Lilly site; routine for expansion but could delay timelines. Lehigh Valley Plant Discussion
• Negative Sentiment: Supreme Court revives Actos litigation — the court’s action reopens potential legal exposure tied to Actos, creating an earnings/contingent‑liability risk that investors will watch for scope and financial impact. Actos Litigation Revival

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.